DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Sin...

FDA Recall #D-0105-2021 — Class III — November 17, 2020

Recall #D-0105-2021 Date: November 17, 2020 Classification: Class III Status: Terminated

Product Description

DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05

Reason for Recall

Cross Contamination with Other Products: trace amounts of octreotide found during testing

Recalling Firm

Fresenius Kabi USA, LLC — Lake Zurich, IL

Classification

Class III — Not likely to cause adverse health consequences.

Product Type

Drugs

Product Quantity

16,986 vials

Distribution

Nationwide USA and Puerto Rico

Code Information

Batch: 6120525, exp 11/2020

Status

Terminated

Voluntary / Mandated

Voluntary: Firm initiated